CalciMedica Reports Preclinical Success for CRAC Channel Inhibitor in Pulmonary Arterial Hypertension

Reuters11-12

CalciMedica Reports Preclinical Success for CRAC Channel Inhibitor in Pulmonary Arterial Hypertension

CalciMedica Inc. has announced the publication of preclinical data in JCI Insight supporting its proprietary CRAC channel inhibitor, CM5480, as a potential therapy for pulmonary arterial hypertension (PAH). The study, conducted in collaboration with leading PAH researchers in France, evaluated CM5480 as both a monotherapy and in combination with standard-of-care PAH treatments in an animal model. The results indicate that CM5480 may mitigate pulmonary hypertension and associated cardiac dysfunction. These preclinical findings have been published, and clinical data from ongoing studies of CalciMedica's lead candidate, Auxora™, in acute kidney injury are expected in the first half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CalciMedica Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA01163) on November 12, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582537301?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582537301","market":"nz","top_or_hot":-1,"title":"CalciMedica Reports Preclinical Success for CRAC Channel Inhibitor in Pulmonary Arterial Hypertension","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CalciMedica Reports Preclinical Success for CRAC Channel Inhibitor in Pulmonary Arterial Hypertension\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CalciMedica Inc. has announced the publication of preclinical data in JCI Insight supporting its proprietary CRAC channel inhibitor, CM5480, as a potential therapy for pulmonary arterial hypertension (PAH). The study, conducted in collaboration with leading PAH researchers in France, evaluated CM5480 as both a monotherapy and in combination with standard-of-care PAH treatments in an animal model. The results indicate that CM5480 may mitigate pulmonary hypertension and associated cardiac dysfunction. These preclinical findings have been published, and clinical data from ongoing studies of CalciMedica's lead candidate, Auxora™, in acute kidney injury are expected in the first half of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CalciMedica Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA01163) on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CalciMedica Reports Preclinical Success for CRAC Channel Inhibitor in Pulmonary Arterial Hypertension</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCalciMedica Reports Preclinical Success for CRAC Channel Inhibitor in Pulmonary Arterial Hypertension\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-12 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CalciMedica Reports Preclinical Success for CRAC Channel Inhibitor in Pulmonary Arterial Hypertension\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CalciMedica Inc. has announced the publication of preclinical data in JCI Insight supporting its proprietary CRAC channel inhibitor, CM5480, as a potential therapy for pulmonary arterial hypertension (PAH). The study, conducted in collaboration with leading PAH researchers in France, evaluated CM5480 as both a monotherapy and in combination with standard-of-care PAH treatments in an animal model. The results indicate that CM5480 may mitigate pulmonary hypertension and associated cardiac dysfunction. These preclinical findings have been published, and clinical data from ongoing studies of CalciMedica's lead candidate, Auxora™, in acute kidney injury are expected in the first half of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CalciMedica Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA01163) on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL10jX1G:1","article_id":"2582537301","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582537301","pubTimestamp":1762948931,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CalciMedica Inc. has announced the publication of preclinical data in JCI Insight supporting its proprietary CRAC channel inhibitor, CM5480, as a potential therapy for pulmonary arterial hypertension . The study, conducted in collaboration with leading PAH researchers in France, evaluated CM5480 as both a monotherapy and in combination with standard-of-care PAH treatments in an animal model. The results indicate that CM5480 may mitigate pulmonary hypertension and associated cardiac dysfunction. These preclinical findings have been published, and clinical data from ongoing studies of CalciMedica's lead candidate, Auxora, in acute kidney injury are expected in the first half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CalciMe","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","CALC":"CALCIMEDICA"},"translate_title":"CalciMedica报告CRAC通道抑制剂治疗肺动脉高压的临床前成功","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CALC":0.9},"content_text":"CalciMedica Reports Preclinical Success for CRAC Channel Inhibitor in Pulmonary Arterial Hypertension\n    \n\n        CalciMedica Inc. has announced the publication of preclinical data in JCI Insight supporting its proprietary CRAC channel inhibitor, CM5480, as a potential therapy for pulmonary arterial hypertension (PAH). The study, conducted in collaboration with leading PAH researchers in France, evaluated CM5480 as both a monotherapy and in combination with standard-of-care PAH treatments in an animal model. The results indicate that CM5480 may mitigate pulmonary hypertension and associated cardiac dysfunction. These preclinical findings have been published, and clinical data from ongoing studies of CalciMedica's lead candidate, Auxora™, in acute kidney injury are expected in the first half of 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CalciMedica Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA01163) on November 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582537301","isCrawlerRequest":true}